Compare Abbott Laboratories (ABT) vs Carnival Corp (CCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Carnival Corp — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Carnival Corp trades at $25.63 (market cap $36.54B). The key difference: Abbott Laboratories is far larger — about 4.6× Carnival Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CCL | |
|---|---|---|
Market Cap | $166.94B | $36.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $33.99 |
52-Week Low | $82.57 | $23.89 |
Enterprise Value | $193.69B | $60.47B |
Dividend Yield | 2.63% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Carnival Corporation (CCL) trades at $26.68, down 4.41% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamental recovery with revenue growing to $26.62B in 2025 and net income reaching $2.76B. Positive analyst sentiment exists with a $35.45 consensus price target, though near-term headwinds in European demand and cost pressures are noted.
The outlook for CCL is cautiously optimistic. Strong booking trends and debt reduction support long-term growth, but investors face risks from geopolitical issues, fuel costs, and competitive pressures. The stock presents potential upside from current levels if execution continues, but requires monitoring of guidance and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →
